


Fig. S6

A

Sample	Section	DLL3 RNA score	% Positive	Comments
Animal 1	1	1	<10%	
	2	1	<10%	Subset of cells score 2
	3	1	<10%	Subset of cells score 2
	4	2	<10%	Localized in ventricular system
Animal 2	1	1	<10%	
	2	1	<10%	
	3	1	<10%	Subset of cells score 2
	4	2	<10%	Localized in ventricular system
Animal 3	1	1	<10%	
	2	1	<10%	
	3	2	<10%	
	4	2	<10%	



Green circle: subset of cells score 2

RNA score 0 = No staining or <1 RNA molecule / 10 cells, 1 = 1-3 RNA molecules/cell, 2 = 4-9 RNA molecules/cell, no or very few dot clusters, 3 = 10-15 RNA molecules/cell and/or <10% dots are in clusters, 4 = >15 RNA molecules/cell and/or >10% dots are in clusters. Percentage of cells positive is scored visually based on number of cells with >1 dot/cell and binned into categories (i.e., 0%, 1-25%, 26-50%, 51-75%, 76-99%, 100%)






Fig. S6 continued




Fig. S6. Infusion of DLL3 CAR T cells did not induce toxicity in non-tumor-bearing model or subcutaneous tumor model. (A) Mouse brain tissues express DLL3 RNA. Brain tissues from three tumor-free and treatment-free NSG mice were harvested and used for single-color chromogenic RNAscope assay with mouse DLL3 specific probe. Discrete red dots corresponded to individual RNA targets. Visual scoring is performed by a qualified scientist to assign a single score to a sample based on the predominant staining pattern throughout the entire sample. (B) T cells were not detected in brain or pituitary samples from non-tumor bearing animals injected with a high dose (8×10^6) of NTD or DLL3 CAR T cells. Tissues were collected 1, 2, or 4 weeks post T cell injection. Scale bars represent 200 μm . Orange arrows point to T cells in the tissues. (C) DLL3 CAR T cells did not induce obvious changes of body weight throughout the study. (D) Serum was collected from animals treated with NTD or DLL3 CAR T cells on day 29, 32 and 36 post T cell infusion and analyzed using meso-scale discovery (MSD) to measure cytokines. Serum collected on day 32 from DLL3 CAR T treated animals has the highest levels of IFN γ . (E) NTD or DLL3 CAR T cells were injected into animals bearing LN229-mDLL3 subcutaneous tumors. A subset of animals were euthanized on day 32 (time of peak of CAR T activity) post CAR T infusion to analyze T cell infiltration into tumor, pituitary and brain. Error bars represent SEM, n=5. (F) IHC study using anti-human CD45 antibody revealed dense infiltration into subcutaneous tumor and sparse infiltration into pituitary tissues. (G) Despite low levels of T cell infiltration into pituitary tissues, pituitary hormones (ADH and oxytocin) can still be detected using IHC, suggesting hormone-secreting function of pituitary was not affected. (H) Surface DLL3 protein was not detected on disassociated mouse pituitary cells using flow cytometry. Disassociated mouse pituitary cells were stained with 2ug/ml of clone 4, clone 9 or isotype control antibody followed by anti-human IgG secondary antibody conjugated with PE. (I) DLL3 protein was not detected in mouse pituitary samples using IHC. (J) Design of in vitro cytotoxicity study (K) Surface staining for CD25 and 41BB of DLL3 CAR T cells co-cultured with targets for 3 days, demonstrating that mouse pituitary cells do not activate DLL3 CAR Ts. Error bars represent standard deviation, n=3. (L) DLL3 CAR Ts do not secrete cytokines when co-cultured with mouse pituitary cells. Error bars represent standard deviation, n=3.